ANAPTYSBIO, INC. Increase (Decrease) in Contract with Customer, Liability
ANAPTYSBIO, INC. (ANAB) reported Increase (Decrease) in Contract with Customer, Liability of $0 for the 12-month period ending 2018-12-31, per its 10-K filed 2019-02-28.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerLiability · last filed 2019-02-28
- ANAPTYSBIO, INC. increase (decrease) in contract with customer, liability for fiscal 2018 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in contract with customer, liability for fiscal 2017 was $0.00.
- ANAPTYSBIO, INC. increase (decrease) in contract with customer, liability for fiscal 2016 was -$2.94M.
| Period end | Increase (Decrease) in Contract with Customer, Liability 12 month |
|---|---|
| 2018-12-31 | $0.00 10-K · filed 2019-02-28 |
| 2017-12-31 | $0.00 10-K · filed 2019-02-28 |
| 2016-12-31 | -$2.94M 10-K · filed 2019-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |